CLEAR 試験: BPH 治療のための ClearRing システムの安全性と有効性の評価
良性前立腺肥大症の治療における ClearRing システムの安全性と有効性の評価
The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH. During the procedure an implant is delivered into the prostate tissue obstructing the urethra and restricting urine flow. The delivery system uses a static diathermy incision mechanism to make a circumferential incision in the tissue surrounding the prostatic urethra into which the Omega shaped permanent implant is placed. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male ≥50 years of age
- Diagnosed with symptomatic benign prostatic hyperplasia (BPH).
- International Prostate Symptom Score (IPSS) >13.
- Peak flow rate ≤ 12 ml/sec (with voided volume ≥ 125ml).
- Participant understands and is willing to the informed consent form.
- Prostate Volume between 30cc and 80cc.
- Prostate length ≥3cm and ≤5cm
Exclusion Criteria:
-
Concomitant participation in another interventional study.
-
Unable to comply with the clinical protocol including all the follow-up requirements.
-
Vulnerable population such as inmates or developmentally delayed individuals.
-
Significant comorbidities which would affect study participation.
-
Diagnosed or suspected prostate cancer. If suspected, prostate cancer must be ruled out.
-
Any medical condition or treatment, which in the opinion of the investigator may interfere with the procedure, such as:
- Use of concomitant medications (e.g., anticholinergics, antispasmodics, or antidepressants) affecting bladder function.
- Patient with coagulopathy due to medications or congenital condition - inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure; low dose aspirin therapy not prohibited.
- Alpha-blockers within 2 weeks of pre-treatment (baseline) evaluation.
- Taking 5-alpha reductase inhibitors (5-ARI) within 6 months (3 months for type II 5-ARI) of pre-treatment (baseline) evaluation unless evidence of same drug dose for at least 6 months with a stable voiding pattern (the drug dose should not be altered or discontinued throughout the study).
- Patient is taking steroids. [Note: Patients approved for the trial who are using the above medications will continue using them after the trial, except for Alpha blockers]
-
Previous prostate surgery such as: TURP, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate.
-
Compromised renal function due to obstructive uropathy.
-
Active Urinary Tract Infection (UTI).
-
Obstructive or protruding median lobe
-
American Society of Anaesthesiologists score (ASA) > 3.
-
Known neurogenic bladder or neurological disorders that might affect bladder or function.
-
Recent myocardial infarction (less than three months).
-
Concomitant bladder stones.
-
Current gross hematuria.
-
Active or history of epididymitis within the past 3 months.
-
Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate.
-
Confirmed or suspected malignancy of bladder.
-
History or presence of strictures in the anterior urethra or bladder neck contracture or detrusor muscle spasms.
-
Other Urethral conditions that may prevent insertion of Delivery Device into prostatic urethra.
-
Bacterial prostatitis within the last 12 months.
-
Previous rectal surgery, other than hemorrhoidectomy.
-
Current uncontrolled diabetes (i.e., hemoglobin A1c ≥ 9%).
-
Known allergy to nickel or titanium or stainless steel.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:オメガデバイス
|
Omega Implantation |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
IPSSスコアで証明される尿関連症状の改善
時間枠:3ヶ月
|
3ヶ月
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- PA-CP-20
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。